Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .
Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: The AtheroGene Study
Objective —To get a better insight into the role of hemostasis in coronary artery disease ( CAD ) , we assessed the impact of von Willebr and factor ( vWF ) , fibrinogen , thrombin-antithrombin ( TAT ) complexes , D-dimers , and plasmin-antiplasmin ( PAP ) complexes on the risk of cardiovascular event in a prospect i ve cohort of CAD patients . Methods and Results —The prospect i ve Atherogene cohort includes 1057 individuals with an angiographically proven coronary artery disease at baseline . After a median follow-up of 6.6 years , 135 individuals died from a cardiovascular cause and 97 had a nonfatal cardiovascular event . Higher levels of all 5 hemostatic markers at baseline were associated with an increased risk of cardiovascular death , but not of nonfatal event . Except for vWF , these associations remained significant after adjustment for conventional cardiovascular risk factors and C-reactive protein ( CRP ) levels ( P for trend according to increasing tertiles=0.20 , 0.011 , 0.026 , 0.019 , and 0.01 for vWF , fibrinogen , TAT , D-Dimer , and PAP , respectively ) . When including the 5 hemostatic markers in a stepwise Cox regression analysis where conventional risk factors and CRP were forced into the model , fibrinogen and D-dimers remained independently associated with the risk of cardiovascular death . Adjusted hazard ratios ( 95 % CI ) associated with one SD increase of fibrinogen and D-dimers were 1.27 ( 1.04 to 1.55 ) and 1.29 ( 1.09 to 1.53 ) , respectively . Conclusions —In patients with coronary artery disease , fibrinogen and D-dimer levels are independent predictors of subsequent cardiovascular death . Our data support a role of impaired coagulation/fibrinolysis process in the complications of coronary artery disease
Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .